Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (844)

« Back to Publications

Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study.

Young KG. et al, (2026), Diabetes Care, 49, 1115 - 1123

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Schnell O. et al, (2026), Cardiovasc Diabetol, 25

Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.

Zeng G. et al, (2026), Lancet, 407, 1626 - 1638

Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis.

Bidel Z. et al, (2026), Eur Heart J, 47, 1649 - 1657

Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.

Umapathysivam MM. et al, (2026), Genome Med, 18

Worsening Kidney Function and Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic Disease.

Sharma A. et al, (2026), JACC Adv, 5

Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study.

Güdemann LM. et al, (2026), Lancet Reg Health Eur, 61

Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.

Coleman RL. et al, (2026), Diabetes Obes Metab, 28, 1068 - 1075

The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review.

Goshrani A. et al, (2026), Diabetes Care, 49, 197 - 210

Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy.

Standl E. et al, (2025), Cardiovasc Diabetol, 24

Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.

Chadwick J. et al, (2025), J Clin Pharmacol, 65, 1460 - 1473

International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL.

Clarke PM. et al, (2025), Diabetes Care, 48, 1925 - 1931

Precision prescribing of SGLT2-inhibitors in people with type 2 diabetes for primary prevention of heart failure: model development and validation study

Young KG. et al, (2025)

Validation of a treatment selection algorithm for optimal choice of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups

Güdemann LM. et al, (2025)

Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.

Coleman RL. et al, (2025), Cardiovasc Diabetol, 24

Load More

1
2
3
4
5
6
7
...
»